Background: Chronic obstructive pulmonary disease (COPD) and asthma have similar clinical features and are both exacerbated by airway infection. Objective: To determine whether garenoxacin mesylate hydrate (GRNX) added to the standard care for bacterial infection-induced acute exacerbation of asthma or COPD in adults has clinical benefits. Method: This single-arm clinical trial was conducted from January 2015 to March 2016. Adults with a history of asthma or COPD for more than 12 months were recruited within 48 h of presentation with fever and acute deterioration of asthma or COPD requiring additional intervention. Participants were administered 400 mg GRNX daily for 7 days without additional systemic corticosteroids or other antibiotics. The primary outcome was efficacy of GRNX based on clinical symptoms and blood test results after 7 days of treatment. Secondary outcomes were: (1) comparison of the blood test results, radiograph findings, and bacterial culture surveillance before and after treatment; (2) effectiveness of GRNX after 3 days of administration; (3) analyzation of patient symptoms based on patient diary; and (4) continued effectiveness of GRNX on 14th day after the treatment (visit 3). Results: The study included 44 febrile patients (34 asthma and 10 COPD). Frequently isolated bacteria included Moraxella catarrhalis (n = 6) and Klebsiella pneumoniae (n = 4). On visit 2, 40 patients responded, and no severe adverse events were observed. All secondary outcomes showed favorable results. Conclusion: GRNX effectively treated asthma and COPD patients with acute bacterial infection without severe adverse events. Further research with a larger study population is needed.

1.
Papi
A
,
Brightling
C
,
Pedersen
SE
,
Reddel
HK
. Asthma. Lancet.
2017
. pii: S0140-6736(17)33311-1.
2.
Mathers
CD
,
Loncar
D
.
Projections of global mortality and burden of disease from 2002 to 2030
.
PLoS Med
.
2006
Nov
;
3
(
11
):
e442
.
[PubMed]
1549-1277
3.
Ichinose
M
,
Sugiura
H
,
Nagase
H
,
Yamaguchi
M
,
Inoue
H
,
Sagara
H
, et al.;
Japanese Society of Allergology
.
Japanese guidelines for adult asthma 2017
.
Allergol Int
.
2017
Apr
;
66
(
2
):
163
89
.
[PubMed]
1323-8930
4.
Ito
K
,
Barnes
PJ
.
COPD as a disease of accelerated lung aging
.
Chest
.
2009
Jan
;
135
(
1
):
173
80
.
[PubMed]
0012-3692
5.
Vos
T
,
Flaxman
AD
,
Naghavi
M
,
Lozano
R
,
Michaud
C
,
Ezzati
M
, et al.
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
.
Lancet
.
2012
Dec
;
380
(
9859
):
2163
96
.
[PubMed]
0140-6736
6.
O’Sullivan
SM
.
Asthma death, CD8+ T cells, and viruses
.
Proc Am Thorac Soc
.
2005
;
2
(
2
):
162
5
.
[PubMed]
1546-3222
7.
Gautier
C
,
Charpin
D
.
Environmental triggers and avoidance in the management of asthma
.
J Asthma Allergy
.
2017
Mar
;
10
:
47
56
.
[PubMed]
1178-6965
8.
Wasser
CD
,
Grushevsky
A
,
Johnson
ST
,
Smith
SR
.
Asthmonia: A clinical definition of a commonly used colloquial term
.
J Asthma
.
2017
Dec
;
•••
:
1
5
.
[PubMed]
0277-0903
9.
Mathews
B
,
Shah
S
,
Cleveland
RH
,
Lee
EY
,
Bachur
RG
,
Neuman
MI
.
Clinical predictors of pneumonia among children with wheezing
.
Pediatrics
.
2009
Jul
;
124
(
1
):
e29
36
.
[PubMed]
0031-4005
10.
Broder
MS
,
Raimundo
K
,
Ngai
KM
,
Chang
E
,
Griffin
NM
,
Heaney
LG
.
Cost and health care utilization in patients with asthma and high oral corticosteroid use
.
Ann Allergy Asthma Immunol
.
2017
May
;
118
(
5
):
638
9
.
[PubMed]
1081-1206
11.
Johnston
SL
,
Szigeti
M
,
Cross
M
,
Brightling
C
,
Chaudhuri
R
,
Harrison
T
, et al.;
AZALEA Trial Team
.
Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial
.
JAMA Intern Med
.
2016
Nov
;
176
(
11
):
1630
7
.
[PubMed]
2168-6106
12.
Earl
CS
,
Keong
TW
,
An
SQ
,
Murdoch
S
,
McCarthy
Y
,
Garmendia
J
, et al.
Haemophilus influenzae responds to glucocorticoids used in asthma therapy by modulation of biofilm formation and antibiotic resistance
.
EMBO Mol Med
.
2015
Aug
;
7
(
8
):
1018
33
.
[PubMed]
1757-4676
13.
Hooper
DC
,
Wolfson
JS
.
Fluoroquinolone antimicrobial agents
.
N Engl J Med
.
1991
Feb
;
324
(
6
):
384
94
.
[PubMed]
0028-4793
14.
Dalhoff
A
.
Immunomodulatory activities of fluoroquinolones
.
Infection
.
2005
Dec
;
33
(
S2
Suppl 2
):
55
70
.
[PubMed]
0300-8126
15.
Fung-Tomc
JC
,
Minassian
B
,
Kolek
B
,
Huczko
E
,
Aleksunes
L
,
Stickle
T
, et al.
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
.
Antimicrob Agents Chemother
.
2000
Dec
;
44
(
12
):
3351
6
.
[PubMed]
0066-4804
16.
Fung-Tomc
JC
,
Gradelski
E
,
Valera
L
,
Huczko
E
,
Bonner
DP
.
Synergistic activity of the novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species
.
Int J Antimicrob Agents
.
2002
Jul
;
20
(
1
):
57
60
.
[PubMed]
0924-8579
17.
Noreddin
AM
,
Reese
AA
,
Ostroski
M
,
Hoban
DJ
,
Zhanel
GG
.
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis
.
Clin Ther
.
2007
Dec
;
29
(
12
):
2685
9
.
[PubMed]
0149-2918
18.
Yamagishi
Y
,
Shibata
T
,
Nakagawa
S
,
Nomura
N
,
Mitsuyama
J
,
Mikamo
H
.
Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones
.
Jpn J Infect Dis
.
2017
Nov
;
70
(
6
):
616
20
.
[PubMed]
1344-6304
19.
Kobayashi
H
,
Watanabe
A
,
Aoki
N
,
Odagiri
S
,
Sano
Y
,
Saito
A
.
Clinical phase II study of garenoxacin in patients with respiratory tract infections -openlabel, multicenter, noncomparative- Jpn
.
J Chemother
.
2007
;
55
S-1
:
116
26
.1120-009X
20.
Kohno
S
,
Watanabe
A
,
Aoki
N
,
Tateda
K
,
Taniguchi
H
,
Niki
Y
, et al.
Clinical phase III open-labeled study of oral garenoxacin in patients with respiratory tract infection by penicillin-resistant Streptococcus pneumoniae
.
Jpn J Chemother
.
2007
;
55
S-1
:
185
93
.
21.
Zhanel
GG
,
Palatnick
L
,
Nichol
KA
,
Low
DE
,
Hoban
DJ
;
CROSS Study Group
.
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
.
Antimicrob Agents Chemother
.
2003
Jun
;
47
(
6
):
1875
81
.
[PubMed]
0066-4804
22.
Huang
YJ
,
Nelson
CE
,
Brodie
EL
,
Desantis
TZ
,
Baek
MS
,
Liu
J
,
Woyke
T
,
Allgaier
M
,
Bristow
J
,
Wiener-Kronish
JP
, et al.;
National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network
. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol
2011
; 127:372–381.e1–e3.
23.
Hilty
M
,
Burke
C
,
Pedro
H
,
Cardenas
P
,
Bush
A
,
Bossley
C
, et al.
Disordered microbial communities in asthmatic airways
.
PLoS One
.
2010
Jan
;
5
(
1
):
e8578
.
[PubMed]
1932-6203
24.
Wang
Z
,
Singh
R
,
Miller
BE
,
Tal-Singer
R
,
Van Horn
S
,
Tomsho
L
,
Mackay
A
,
Allinson
JP
,
Webb
AJ
,
Brookes
AJ
,
George
LM
,
Barker
B
,
Kolsum
U
,
Donnelly
LE
,
Belchamber
K
,
Barnes
PJ
,
Singh
D
,
Brightling
CE
,
Donaldson
GC
,
Wedzicha
JA
,
Brown
JR
; COPDMAP. Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax.
2017
. pii: thoraxjnl-2017-210741.
25.
Mayhew
D
,
Devos
N
,
Lambert
C
,
Brown
JR
,
Clarke
SC
,
Kim
VL
,
Magid-Slav
M
,
Miller
BE
,
Ostridge
KK
,
Patel
R
,
Sathe
G
,
Simola
DF
,
Staples
KJ
,
Sung
R
,
Tal-Singer
R
,
Tuck
AC
,
Van Horn
S
,
Weynants
V
,
Williams
NP
,
Devaster
JM
,
Wilkinson
TMA
;
AERIS Study Group
.
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.
Thorax.
2018
. pii: thoraxjnl-2017-210408.
26.
Ianiro
G
,
Tilg
H
,
Gasbarrini
A
.
Antibiotics as deep modulators of gut microbiota: between good and evil
.
Gut
.
2016
Nov
;
65
(
11
):
1906
15
.
[PubMed]
0017-5749
27.
Dicker
AJ
,
Crichton
ML
,
Cassidy
AJ
,
Brady
G
,
Hapca
A
,
Tavendale
R
,
Einarsson
GG
,
Furrie
E
,
Elborn
JS
,
Schembri
S
,
Marshall
SE
,
Palmer
CNA
,
Chalmers
JD
.
Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD.
Thorax.
2017
. pii: thoraxjnl-2016-209931.
28.
Chiu
CY
,
Chan
YL
,
Tsai
YS
,
Chen
SA
,
Wang
CJ
,
Chen
KF
, et al.
Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood
.
Sci Rep
.
2017
May
;
7
(
1
):
1820
.
[PubMed]
2045-2322
29.
Homma
T
,
Kato
A
,
Sakashita
M
,
Norton
JE
,
Suh
LA
,
Carter
RG
, et al.
Involvement of Toll-like receptor 2 and epidermal growth factor receptor signaling in epithelial expression of airway remodeling factors
.
Am J Respir Cell Mol Biol
.
2015
Apr
;
52
(
4
):
471
81
.
[PubMed]
1044-1549
30.
Shiratori
B
,
Zhang
J
,
Usami
O
,
Chagan-Yasutan
H
,
Suzuki
Y
,
Nakajima
C
, et al.
Quinolone-induced upregulation of osteopontin gene promoter activity in human lung epithelial cell line A549
.
Antimicrob Agents Chemother
.
2012
Jun
;
56
(
6
):
2868
72
.
[PubMed]
0066-4804
31.
Hara
S
,
Ishimatsu
Y
,
Mukae
H
,
Sakamoto
N
,
Kakugawa
T
,
Fujita
H
, et al.
Anti-inflammatory effects of garenoxacin on IL-8 production and ERK1/2 activation induced by lipopolysaccharides in A549 and THP-1 cells
.
Eur J Pharmacol
.
2011
Oct
;
668
(
1-2
):
264
70
.
[PubMed]
0014-2999
32.
Homma
T
,
Kato
A
,
Sakashita
M
,
Takabayashi
T
,
Norton
JE
,
Suh
LA
, et al.
Potential Involvement of the Epidermal Growth Factor Receptor Ligand Epiregulin and Matrix Metalloproteinase-1 in Pathogenesis of Chronic Rhinosinusitis
.
Am J Respir Cell Mol Biol
.
2017
Sep
;
57
(
3
):
334
45
.
[PubMed]
1044-1549
33.
Horiguchi
T
,
Miyazaki
J
,
Ohira
D
,
Watanabe
Y
,
Hayashi
N
,
Kobayashi
K
, et al.
Usefulness of sparfloxacin against Chlamydia pneumoniae infection in patients with bronchial asthma
.
J Int Med Res
.
2005
Nov-Dec
;
33
(
6
):
668
76
.
[PubMed]
0300-0605
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.